RAS/MAPK

BOSTON — September 24, 2026 Verastem Oncology announced that molecular profiling and tumor biomarker findings from the Phase 2...

BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...

MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...